drugset / Trial / NCT01327664

Study to Evaluate the Long Term Use of Treatment With AIN457 for Uveitis

NCT01327664

Phase 3 Withdrawn Novartis Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will provide patients who have completed the AIN457 Phase II and Phase III clinical trials in non-infectious uveitis continued access to treatment with AIN457 while collecting safety data and information on long term clinical use of treatment with AIN457.

Timeline

Start
2011-03
Primary completion
2014-05
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Secukinumab Monoclonal antibody 300 mg Subcutaneous

Indications